Loading resource…

Toronto General Hospital Research Institute, University Health Network, The George Institute for Global Health, Royal North Shore Hospital, New Arch Consulting, Janssen, Inc.
The research focuses on the effects of canagliflozin on cardiovascular and kidney events in patients with type 2 diabetes. It evaluates a pooled population from two significant trials, CANVAS and CREDENCE, to assess the risk of kidney disease progression. The findings indicate that canagliflozin significantly reduces the risk of adverse kidney outcomes across different levels of kidney function, including those with severely reduced eGFR. This analysis contributes to understanding the broader implications of canagliflozin in managing kidney health in diabetic patients.
No account needed